Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm.
James H ColeJoel RaffelTim FriedeE Ann YehWallace J BrownleeDeclan ChardNicola De StefanoChristian EnzingerLukas PirpamerMassimo FilippiClaudio GasperiniMaria Assunta RoccaAlex RoviraSerena RuggieriJaume Sastre-GarrigaMaria Laura StromilloBernard M J UitdehaagHugo VrenkenFrederik BarkhofRichard St John NicholasOlga Ciccarellinull nullPublished in: Annals of neurology (2020)
The brain-age paradigm is sensitive to MS-related atrophy and clinical progression. A higher brain-PAD at baseline was associated with more rapid disability progression and the rate of change in brain-PAD related to worsening disability. Potentially, "brain-age" could be used as a prognostic biomarker in early-stage MS, to track disease progression or stratify patients for clinical trial enrollment. ANN NEUROL 2020 ANN NEUROL 2020;88:93-105.
Keyphrases
- multiple sclerosis
- white matter
- resting state
- early stage
- clinical trial
- functional connectivity
- end stage renal disease
- cerebral ischemia
- mass spectrometry
- chronic kidney disease
- randomized controlled trial
- newly diagnosed
- healthcare
- radiation therapy
- lymph node
- study protocol
- peritoneal dialysis
- cross sectional
- neural network
- brain injury
- sensitive detection
- patient reported